Stocks Merck & Co Inc

More

  • graphic_final_trade.jpg

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • graphic_word_ofthe_street.jpg

    A pair of crucial earnings "beats" capped off a day that defied expectations as the market ended higher despite having every reason to sell off. Find out what happened and how to trade it.

  • Stocks closed higher as optimism prevailed, even in the face of $122-a-barrel oil. Techs got a boost from speculation that a deal between Microsoft and Yahoo is still possible.

  • Stocks declined as oil surpassed $122 a barrel and Fannie Mae delivered disappointing results.

  • merck_logo.jpg

    After the closing bell yesterday, Merck announced that it plans to get rid of 12-hundred or around 15 percent of its sales reps. Like Schering-Plough, the company is having to adjust to lower sales of its Vytorin and Zetia cholesterol drugs and on top of that the Food and Drug...

  • Merck, whose earnings have been hurt by patent expirations and declining sales of its Vytorin cholesterol fighter, said Monday it will eliminate another 1,200 members of its U.S. sales force as part of a restructuring begun in late 2005.

  • Financial pain and physical pain may be linked: A new study says people who make less money and work in blue-collar jobs are more prone to be in pain.

  • Dr. Vagelos

    I didn't post yesterday because I was in Philadelphia shooting a story for an upcoming episode of "The Business of Innovation" on CNBC. It's a piece about big pharma and we went to Philly to interview the still very busy former CEO of Merck (two CEOs ago), Dr. Roy Vagelos.

  • It's a booyah-free zone. There goes Swifty!

  • Merck says it has received a warning letter from the Food and Drug Administration over concerns at one of its major vaccine manufacturing plants.

  • graphic_word_ofthe_street.jpg

    The markets dropped a bit as investors eagerly await Wednesday's rate decision. Find out what was moving in the Word on the Street.

  • Stocks closed mixed in thin trading Tuesday as the tide turned in technology's favor. Airline stocks rose as oil prices receded. Merck skidded after an FDA rejection.

  • Stocks pushed higher Tuesday despite concerns about interest rates ahead of the Federal Reserve's decision. Merck skidded after an FDA rejection. Airline stocks rose as oil prices receded.

  • Stocks declined Tuesday amid concerns about interest rates and a slide in consumer confidence. Merck dragged on the Dow industrials after the FDA rejected a key cholesterol drug.

  • merck_HQ2.jpg

    Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.

  • Merck

    U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.

  • Wall Street’s on the edge of its seat ahead of Wednesday’s interest-rate announcement. You should be on the phone with your broker.

  • Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • dice_stock_chart_200.jpg

    Earnings Season shifted into high gear, both corporate results and economic statistics were all over the proverbial map, and investors and traders found opportunities in some unlikely places.

  • AMGEN

    The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.